ONCOLYTICS BIOTECH INC (ONCY) Stock Price, Quote, News and Overview
NASDAQ:ONCY - Nasdaq - CA6823108759 - Common Stock - Currency: USD
ONCY Quote, Performance and Key Statistics
0.421
-0.01 (-2.02%)
The current stock price of ONCY is 0.421 USD. In the past month the price decreased by -25.7%. In the past year, price decreased by -61.38%.
ONCY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.7 | 321.60B | ||
| AMGN | AMGEN INC | 13.07 | 145.89B | ||
| GILD | GILEAD SCIENCES INC | 13.92 | 134.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.65 | 65.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.06B | ||
| ARGX | ARGENX SE - ADR | 99.65 | 35.72B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.49B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.54B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.87B | ||
| BIIB | BIOGEN INC | 8.02 | 18.58B |
Related stock screener links
About ONCY
Company Profile
Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. The firm is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Company Info
ONCOLYTICS BIOTECH INC
804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7
Calgary ALBERTA T2N 1X7 CA
CEO: Matthew C. Coffey
Employees: 28
Phone: 14036707377
ONCOLYTICS BIOTECH INC / ONCY FAQ
What is the stock price of ONCOLYTICS BIOTECH INC today?
The current stock price of ONCY is 0.421 USD. The price decreased by -2.02% in the last trading session.
What is the ticker symbol for ONCOLYTICS BIOTECH INC stock?
The exchange symbol of ONCOLYTICS BIOTECH INC is ONCY and it is listed on the Nasdaq exchange.
On which exchange is ONCY stock listed?
ONCY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ONCOLYTICS BIOTECH INC stock?
9 analysts have analysed ONCY and the average price target is 3.43 USD. This implies a price increase of 713.96% is expected in the next year compared to the current price of 0.421. Check the ONCOLYTICS BIOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ONCOLYTICS BIOTECH INC worth?
ONCOLYTICS BIOTECH INC (ONCY) has a market capitalization of 33.69M USD. This makes ONCY a Nano Cap stock.
How many employees does ONCOLYTICS BIOTECH INC have?
ONCOLYTICS BIOTECH INC (ONCY) currently has 28 employees.
What are the support and resistance levels for ONCOLYTICS BIOTECH INC (ONCY) stock?
ONCOLYTICS BIOTECH INC (ONCY) has a resistance level at 0.56. Check the full technical report for a detailed analysis of ONCY support and resistance levels.
Should I buy ONCOLYTICS BIOTECH INC (ONCY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ONCY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ONCY, evaluating the profitability, health, valuation and growth aspects
- ONCOLYTICS BIOTECH INC (ONCY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ONCOLYTICS BIOTECH INC (ONCY) Sales and EPS estimates to see what analysts future expectations are.
- ONCOLYTICS BIOTECH INC (ONCY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ONCOLYTICS BIOTECH INC (ONCY) Insider and Institutional Ownership to learn about the owners and their transactions.
- ONCOLYTICS BIOTECH INC (ONCY) Stock Chart to make your own analysis
- ONCOLYTICS BIOTECH INC (ONCY) Latest news and press-releases to stay up to date.
Does ONCOLYTICS BIOTECH INC (ONCY) stock pay dividends?
ONCY does not pay a dividend.
When does ONCOLYTICS BIOTECH INC (ONCY) report earnings?
ONCOLYTICS BIOTECH INC (ONCY) will report earnings on 2025-07-30, after the market close.
What is the Price/Earnings (PE) ratio of ONCOLYTICS BIOTECH INC (ONCY)?
ONCOLYTICS BIOTECH INC (ONCY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.29).
What is the Short Interest ratio of ONCOLYTICS BIOTECH INC (ONCY) stock?
The outstanding short interest for ONCOLYTICS BIOTECH INC (ONCY) is 2.92% of its float. Check the ownership tab for more information on the ONCY short interest.
ONCY Technical Analysis
ONCY Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ONCY. ONCY may be in some trouble as it scores bad on both profitability and health.
ONCY Financial Highlights
Over the last trailing twelve months ONCY reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS decreased by -0.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -157.08% | ||
| ROE | -530% | ||
| Debt/Equity | 0.13 |
ONCY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to ONCY. The Buy consensus is the average rating of analysts ratings from 9 analysts.